Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral Research Award: Canada Graduate Scholarships

University of Toronto

$105,000.00

Exploiting natural products and their derivatives to identify novel antifungal strategies against human fungal pathogens

EF 2019-20

Résumé
Invasive fungal infections cause significant morbidity and mortality in vulnerable populations, especially individuals with weakened immune systems. The leading human fungal pathogen, Candida albicans, is one of the most frequently found hospital-borne infections and is rapidly becoming resistant to both first- and second-line antifungals. Furthermore, the number of clinically useful antifungal medications is limited due to toxic side effects and inadequate effectiveness. Current antifungals available in the clinic are limited to only three classes, all of which are vulnerable to resistance. A promising strategy to combat emerging drug-resistant fungi is through combination therapy, as combining drugs has the potential to increase drug effectiveness and can slow the evolution of drug resistance. The goal of my project is to identify and characterize antifungals that engage with new drug targets and enhance the effectiveness of the existing antifungals. To accomplish this, I screened ~20,000 chemicals for activity in the absence and presence of the azole antifungal, fluconazole, against C. albicans. To select compounds with favorable antifungal properties, I assessed each hit compounds' mammalian toxicity, activity against drug resistant isolates, and spectrum of activity across human fungal pathogens. Using this pipeline, I have prioritized one broad-spectrum compound that we discovered targets fatty acid synthesis, a key component of fungal membranes, and one azole-enhancing compound that induces cellular stress by modulating lipid homeostasis. Future experiments will include performing biochemical assays to verify drug mode-of-action. I will also investigate the effect of inhibiting these biological processes on fungal virulence traits and determining the therapeutic potential of these molecules. Overall, this research is poised to unveil novel antifungal targets and expand our knowledge of drug resistance to ultimately treat life-threatening fungal infections.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
417166
Name
Revie Nicole
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Exploiting natural products and their derivatives to identify novel antifungal strategies against human fungal pathogens
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Antifungals; Candida Albicans; Combination Therapy; Drug-Resistant; Infectious Disease; Mycology; Pathogen
Abstract
Invasive fungal infections cause significant morbidity and mortality in vulnerable populations, especially individuals with weakened immune systems. The leading human fungal pathogen, Candida albicans, is one of the most frequently found hospital-borne infections and is rapidly becoming resistant to both first- and second-line antifungals. Furthermore, the number of clinically useful antifungal medications is limited due to toxic side effects and inadequate effectiveness. Current antifungals available in the clinic are limited to only three classes, all of which are vulnerable to resistance. A promising strategy to combat emerging drug-resistant fungi is through combination therapy, as combining drugs has the potential to increase drug effectiveness and can slow the evolution of drug resistance. The goal of my project is to identify and characterize antifungals that engage with new drug targets and enhance the effectiveness of the existing antifungals. To accomplish this, I screened ~20,000 chemicals for activity in the absence and presence of the azole antifungal, fluconazole, against C. albicans. To select compounds with favorable antifungal properties, I assessed each hit compounds' mammalian toxicity, activity against drug resistant isolates, and spectrum of activity across human fungal pathogens. Using this pipeline, I have prioritized one broad-spectrum compound that we discovered targets fatty acid synthesis, a key component of fungal membranes, and one azole-enhancing compound that induces cellular stress by modulating lipid homeostasis. Future experiments will include performing biochemical assays to verify drug mode-of-action. I will also investigate the effect of inhibiting these biological processes on fungal virulence traits and determining the therapeutic potential of these molecules. Overall, this research is poised to unveil novel antifungal targets and expand our knowledge of drug resistance to ultimately treat life-threatening fungal infections.
Competitiondate
201911
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Revie, Nicole
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~